BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24055076)

  • 21. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.
    Zheng Y; Obeng S; Wang H; Jali AM; Peddibhotla B; Williams DA; Zou C; Stevens DL; Dewey WL; Akbarali HI; Selley DE; Zhang Y
    J Med Chem; 2019 Jan; 62(2):561-574. PubMed ID: 30608693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reporter affinity labels: an o-phthalaldehyde derivative of beta-naltrexamine as a fluorogenic ligand for opioid receptors.
    Le Bourdonnec B; El Kouhen R; Lunzer MM; Law PY; Loh HH; Portoghese PS
    J Med Chem; 2000 Jun; 43(13):2489-92. PubMed ID: 10891107
    [No Abstract]   [Full Text] [Related]  

  • 23. Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors.
    Wang WW; Shahrestanifar M; Jin J; Howells RD
    Proc Natl Acad Sci U S A; 1995 Dec; 92(26):12436-40. PubMed ID: 8618916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological profiles of selective non-peptidic delta opioid receptor ligands.
    Chaturvedi K; Jiang X; Christoffers KH; Chinen N; Bandari P; Raveglia LF; Ronzoni S; Dondio G; Howells RD
    Brain Res Mol Brain Res; 2000 Sep; 80(2):166-76. PubMed ID: 11038249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding mode analyses of NAP derivatives as mu opioid receptor selective ligands through docking studies and molecular dynamics simulation.
    Wang H; Zaidi SA; Zhang Y
    Bioorg Med Chem; 2017 Apr; 25(8):2463-2471. PubMed ID: 28302509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes.
    Pelotte AL; Smith RM; Ayestas M; Dersch CM; Bilsky EJ; Rothman RB; Deveau AM
    Bioorg Med Chem Lett; 2009 May; 19(10):2811-4. PubMed ID: 19364645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
    Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
    Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biaryl piperidines as potent and selective delta opioid receptor ligands.
    Liras S; McHardy SF; Allen MP; Segelstein BE; Heck SD; Bryce DK; Schmidt AW; Vanase-Frawley M; Callegari E; McLean S
    Bioorg Med Chem Lett; 2010 Jan; 20(2):503-7. PubMed ID: 20015649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agonists and antagonists bind to different domains of the cloned kappa opioid receptor.
    Kong H; Raynor K; Yano H; Takeda J; Bell GI; Reisine T
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):8042-6. PubMed ID: 8058754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
    Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
    Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
    Ghirmai S; Azar MR; Cashman JR
    Bioorg Med Chem; 2009 Sep; 17(18):6671-81. PubMed ID: 19683449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.
    Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Beletskaya IO; Selley DE; Zhang Y
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5625-9. PubMed ID: 21788135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. General, kappa, delta and mu opioid receptor antagonists mediate feeding elicited by the GABA-B agonist baclofen in the ventral tegmental area and nucleus accumbens shell in rats: reciprocal and regional interactions.
    Miner P; Shimonova L; Khaimov A; Borukhova Y; Ilyayeva E; Ranaldi R; Bodnar RJ
    Brain Res; 2012 Mar; 1443():34-51. PubMed ID: 22305145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3D modeling, ligand binding and activation studies of the cloned mouse delta, mu; and kappa opioid receptors.
    Filizola M; Laakkonen L; Loew GH
    Protein Eng; 1999 Nov; 12(11):927-42. PubMed ID: 10585498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynorphin A(1-17)-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats.
    Silva RM; Grossman HC; Hadjimarkou MM; Rossi GC; Pasternak GW; Bodnar RJ
    J Pharmacol Exp Ther; 2002 May; 301(2):513-8. PubMed ID: 11961051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the unique pharmacology of a novel opioid receptor, ZFOR1, using molecular modeling and the 'message-address' concept.
    McFadyen IJ; Metzger TG; Paterlini MG; Ferguson DM
    Protein Eng; 2001 Dec; 14(12):953-60. PubMed ID: 11809925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.
    Le Bourdonnec B; Barker WM; Belanger S; Wiant DD; Conway-James NC; Cassel JA; O'Neill TJ; Little PJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2006-12. PubMed ID: 18313920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.
    Yuan Y; Stevens DL; Braithwaite A; Scoggins KL; Bilsky EJ; Akbarali HI; Dewey WL; Zhang Y
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4731-4. PubMed ID: 22683223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of irreversible binding of beta-funaltrexamine to the cloned rat mu opioid receptor.
    Chen C; Xue JC; Zhu J; Chen YW; Kunapuli S; Kim de Riel J; Yu L; Liu-Chen LY
    J Biol Chem; 1995 Jul; 270(30):17866-70. PubMed ID: 7629089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.